Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilead

Gilead Sciences

Gilead and Achillion see 100% success rate in hep C trial

New combination treatment aims to compete in a rapidly evolving market for the disease

Gilead Sciences

Gilead cuts hepatitis C drug prices in Germany

Discount on Sovaldi and Harvoni follows similar agreement in France

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

France agrees lowest Sovaldi pricing in EU

Government brings cost of hepatitis C drug to €5,000 below list price

- PMLiVE

Triple therapy ‘might cure hep C in six weeks’

Phase II trials shows promise for Merck and Gilead drugs

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

Gilead Sciences

Gilead gets EU nod for cancer drug Zydelig

Approved for patients with chronic lymphocytic leukaemia and follicular lymphoma

- PMLiVE

Gilead’s simtuzumab fails pancreatic cancer trial

Showed little difference in progression-free survival compared to placebo results

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links